Divi's Laboratories has reported results for second quarter ended September 30, 2024 (Q2FY25).
The company has reported 51.46% rise in its net profit at Rs 518 crore for the quarter ended September 30, 2024 as compared to Rs 342 crore for the same quarter in the previous year. Total income of the company increased by 23.25% at Rs 2,407 crore for Q2FY25 as compared to Rs 1,953 crore for the corresponding quarter previous year.
On consolidated basis, the company has reported 46.55% rise in net profit at Rs 510 crore for Q2FY25 as compared to Rs 348 crore for the same quarter in the previous year. Total income of the company increased by 22.51% at Rs 2,444 crore for Q2FY25 as compared to Rs 1,995 crore for the corresponding quarter previous year.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1669.20 |
| Dr. Reddys Lab | 1233.00 |
| Cipla | 1232.25 |
| Zydus Lifesciences | 937.65 |
| Lupin | 2328.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: